MaaT Pharma to Present Updates from Early Access Program at the 2024 ASH Annual Meeting Demonstrating Prolonged Long-Term Survival in…
Categorie
Press Releases
MaaT Pharma Provides Third Quarter 2024 Business and Financial Results and Announces Management Changes Completion of enrollment in the European…
November 5, 2024
MaaT Pharma Completes Recruitment of its ARES Phase 3 Trial for MaaT013 to Treat Acute Graft-versus-Host Disease Last patient treated…
October 15, 2024
MaaT Pharma Publishes its Half Year 2024 Results and Provides a Business Update Positive efficacy and safety data of…
September 19, 2024
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Article 223-16 of…
September 9, 2024
MaaT Pharma To Present and Participate in Investor and Medical Conferences in September Lyon, France, September 4, 2024 – 7:30am…
September 4, 2024
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Article 223-16 of…
August 9, 2024
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Article 223-16 of…
July 5, 2024
MaaT Pharma: Half-year Report and an Increase of the Resources Allocated to the Liquidity Contract With Kepler Cheuvreux Lyon, France,…
July 5, 2024
MaaT Pharma Announces First DSMB Positive Review of Ongoing Phase 2 Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT Independent…
July 2, 2024
We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.
Ressources
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.